Ribonucleic acid (RNA) is one of life's most versatile molecules, with roles going far beyond being a messenger of genetic ...
Backed by fresh European financing, BioNTech’s Kigali facility is emerging as the cornerstone of Africa’s mRNA vaccine ...
RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has ...
A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...
Arcturus Therapeutics (ARCT) stock falls as Citi downgrades the company following weak mid-stage trial data for its cystic ...
Helping certain genetic information travel to specific parts of nerve cells can ease motor symptoms in SMA, a study in mice ...
PreliminaryResultsYield43%OverallResponseRates(viaRECIST)intheEfficacyPopulationDataDemonstrateREM-422,theFirst-in-ClassSmallMoleculeMYBmRNADegrad ...
Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...
Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with ...
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients ...